|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Institute of Pathology, Consultation and
Reference Center for Lymph Node Pathology and Haematopathology,
University Hospital Benjamin Franklin, Free University Berlin, Germany.
BCL-6 is essential for germinal center formation and
thus for affinity maturation of immunoglobulin (Ig) genes
by somatic mutations. The 5'-noncoding region of the BCL-6
gene is even a target for the mutation machinery. Translocations of the
BCL-6 gene to heterologous promoters and mutations of its
5'-noncoding regulatory region were reported to be potential mechanisms
for deregulating BCL-6 expression and for playing a role in the genesis of non-Hodgkin lymphoma. In line with this hypothesis is the
observation that B-cell lymphoma with somatic mutations, such as
diffuse large B-cell lymphoma and follicular lymphoma, also carry
BCL-6 mutations, some of which are recurrently detectable.
Classic Hodgkin disease (cHD) is also derived from B cells with high
loads of somatic mutations and thus a further candidate for
BCL-6 mutations. To determine the presence and potential
role of BCL-6 mutations in cHD, the 5'-noncoding
BCL-6 proportion of single Hodgkin and Reed-Sternberg (HRS)
cells from 6 cases of cHD and 6 cases of HD-derived cell lines was
analyzed. All B-cell-derived HD cases and cell lines harbored
BCL-6 mutations. In contrast, both T-cell-derived HD cases
and cell lines were devoid of BCL-6 mutations. With only one exception, there were no lymphoma-specific recurrent
BCL-6 mutations detected, and BCL-6 protein was absent from
the HRS cells of most cases. In conclusion, (1) somatic
BCL-6 mutations are restricted to cHD cases of B-cell
origin, and (2) the BCL-6 mutations represent mostly
irrelevant somatic base substitutions without consequences for
BCL-6 protein expression and the pathogenesis of cHD.
(Blood. 2001;97:2401-2405) The proto-oncogene BCL-6 is, with the
exception of immunoglobulin (Ig) heavy and light chain
genes, the only gene that is known to be significantly somatically
mutated in the course of the germinal center (GC) reaction in B
cells.1,2 These somatic mutations occur preferentially in
the 5'-noncoding region of the BCL-6 gene.1 In
addition, somatic hypermutations, as well as translocations, in the
BCL-6 regulatory element are frequently found in B-cell
lymphoma originating from GC or post-GC B cells.3-7 It is
postulated that these alterations affecting the transcriptional activity of the BCL-6 gene are involved in the pathogenesis
of several lymphoma entities.5-7 This holds especially
true for follicular lymphoma (FL) and diffuse large B-cell lymphoma
(DLBCL), which harbor, in addition to their highly mutated
Ig genes, alterations in the 5'-noncoding region of the
BCL-6 gene.3,5
The tumor cells of classical Hodgkin disease (cHD), the Hodgkin and
Reed-Sternberg (HRS) cells, are also derived from highly mutated GC or
post-GC B cells in the vast majority of cases.8-10 Only a
small proportion of cases originate from T cells, as shown by their
rearranged TCR genes.11,12 It is therefore
tempting to speculate that the 5'-noncoding region of the
BCL-6 gene is mutated in HRS cells and, comparable to the
situation described for FL and DLBCL, involved in the pathogenesis of
cHD. However, BCL-6 is expressed in only a proportion of cHD
cases,13 thereby raising the question of the significance
of BCL-6 in HD. Furthermore, it is interesting to see
whether there are differences in the mutational pattern of
BCL-6 in HRS cells of B- or T-cell genotype supporting the
view of 2 different disease entities.
To clarify the mutational status of BCL-6 in cHD, we
isolated single HRS cells from 6 patients and analyzed the 5'-noncoding region of the BCL-6 gene. Furthermore, nonneoplastic cells
were isolated for comparison. Our data show that all patients with cHD
with a B-cell genotype harbor mutated BCL-6 genes, whereas patients with cHD with T-cell genotype lack mutations. This lends further credit to the hypothesis that cHD of T- and B-cell genotype are
biological distinct entities.
Tissue samples, cell lines, and immunostaining
DNA extraction
Immunohistochemistry Both lymph node biopsies and HD-derived cell lines were immunohistochemically analyzed by a panel of monoclonal antibodies against CD30 (Ber-H2), CD15 (C3D1), LMP-1 (CS1-4), CD20 (L26), BCL-6 (594), CD3 (UCHT1), CD8 (C8/144B) (all from Dako Diagnostics, Hamburg, Germany), and perforin (P1-8) (Kamiya Biomedical Company, Seattle, WA). Immunostaining was performed on frozen or formalin-fixed, paraffin-embedded sections employing the of alkaline phosphatase antialkaline phosphatase (APAAP) technique.14 Paraffin-embedded sections were pretreated by pressure cooking as previously described.15Single cell isolation Using a hydraulic micromanipulation device, CD30+ HRS cells were isolated from immunostained frozen tissue sections from 6 patients with cHD.16 We pooled 2-7 single HRS cells to obtain higher PCR amplification rates. All cases were analyzed at least twice in completely independent cell isolation procedures and PCR assays. In cases with mutated BCL-6 5'-noncoding sequences in the HRS cells (reference sequence AF191831),5 additional CD30 reactive cells were investigated to rule
out individual polymorphism. Furthermore, buffers overlaying the tissue
sections during the cell isolation process were used as
negative controls.
PCR Isolated cells were digested with 0.1 mg/mL proteinase K (Boehringer Mannheim, Mannheim, Germany) for 1 hour at 50°C and, after heat denaturation of the enzyme, subjected to a seminested BCL-6 PCR. The PCR was carried with Taq buffer (PerkinElmer) supplemented with 1.5 mM magnesium dichloride (MgCl2), 0.8 mM dNTP (deoxynucleoside-5'-triphosphate), 50 ng of each primer, and 2 U Taq DNA polymerase (PerkinElmer). The first round of amplification was performed employing bcl6up (5'-ATG CTT TGG CTC CAA GTT-3') and bcl6low (5'-CAC GAT ACT TCA TCT CAT C-3'). For re-amplification the bcl6low primer was replaced by a nested bcl6low2 primer (5'-CGG CTC GAA GGC AGG-3'). The PCR conditions were 96°C for 15 seconds, 62°C for 1 minute, and 72°C for 50 seconds for the initial 5 cycles. For the remaining 35 cycles the annealing conditions were reduced to 60°C for 30 seconds. The re-amplification was carried out under the same PCR conditions with the exception of 10 initial cycles of higher stringency instead of 5 cycles. Negative and positive controls for single cell analysis were performed under the same conditions, whereas 400 ng cell line DNA was amplified by only one round of PCR. Reaction mixtures were analyzed on 1.5% agarose gels and stained with ethidium bromide. Bands of appropriate size were excised from the gels and purified with the Qiaex-2 DNA isolation kit (Qiagen).Cloning and sequencing of PCR products Purified PCR products obtained from B-cell-derived HD cell lines were cloned (Topo cloning, Invitrogen, Westbrook, ME), and 10-20 randomly selected colonies were sequenced by fluorescence chain termination technique (Bigdye; ABI, Weiterstadt, Germany) on an automated sequencer (ABI 377A, ABI). The resulting sequences were compared to published data bank sequences (GenBank) and our own unpublished sequences.
Genotype and immunophenotype of the HRS cells The genotype and expression profile of the 6 cHD cases used for the present study have been described elsewhere.12 In brief, the HRS cells of 4 cases harbored highly mutated rearranged IgH genes, whereas the other 2 cases displayed HRS cells with clonal TCR rearrangements.12,16 Both cases with rearranged TCR genes displayed a strong expression of perforin in all tumor cells. One of the cases with a B-cell genotype (patient no. 5) was positive for the Epstein-Barr virus (EBV)-encoded LMP-1 protein (Table 1).
The expression of BCL-6 was heterogeneous among the cases and cell
lines investigated. Two cHD cases (one case with TCR
rearrangement and one with IgH rearrangement) disclosed a
BCL-6 expression of virtually all HRS cells, whereas BCL-6 was
completely absent in the HRS cells of 2 further cases (both with
IgH rearrangement). In the remaining 2 cases, scattered HRS
cells were BCL-6+. Imunostaining of HD-derived cell lines
for BCL-6 revealed single BCL-6+ cells in cell lines L1236,
L428, KMH2, and Holden. Up to 10% of the cells were positive only in
cell lines L540 and L591 (Table 2).
BCL-6 sequence analysis in single cells and cell lines For analysis of the 5'-noncoding region of the BCL-6 gene, 202 single HRS cells were isolated from 6 cases of cHD. In addition, 172 single CD30 reactive lymphoid cells were
extracted from the same tissue specimens to determine irrelevant
individual polymorphism. Furthermore, 6 HD-derived cell lines were
included in this study. From each cell line, 5-18 sequences were
analyzed by cloning of the PCR products. Only base substitutions that
were repeatedly found in completely independent analyses were
considered as real mutations. Unique alterations were regarded as
errors of the Taq polymerase. The BCL-6 sequences
of all 4 B-cell-derived HD cases and the 4 B-cell-derived HD cell
lines carried 1-15 somatic alterations (Tables
3 and 4).
Approximately half of these mutations represented transitions, whereas the remaining half represented transversions. The
base substitutions observed in the CD30+ HRS cells were not
detectable in CD30 reactive cells isolated from the same
tissue sections. This clearly indicates that the BCL-6
mutations observed in HRS cells are somatic and were most likely
introduced in the course of the GC reaction. Most of these mutations
are new and are not yet described elsewhere. The remaining 4 mutations
were recurrent.5 However, 2 of these mutations were
located in a RGWY mutation hotspot,5 and another one
occurred at a site that was also reported to be mutated in reactive B
cells.5 Therefore, 3 of 4 recurrent mutations do not
represent lymphoma-specific base substitutions.
In contrast to the B-cell-derived cHD cases and cell lines, both cHD
cases with T-cell genotype, as well as the 2 T-cell-derived HD cell
lines, were unmutated (Tables 3 and 4). To determine whether the
5'-noncoding region of the BCL-6 gene of GC T cells could be
affected by the somatic hypermutation machinery, we isolated 29 GC T
cells identified by their Correlation of the somatic IgH and BCL-6 mutations and BCL-6 protein expression We compared the frequency of somatic mutations found in the 5'-noncoding region of the BCL-6 gene with those published for the IgH genes in corresponding cases (Table 2).12,17 Although all cases with IgH mutations displayed BCL-6 mutations, there was no correlation in the number of mutations. Furthermore, there was no correlation between the number of BCL-6 mutations and the BCL-6 expression.
Previous studies have shown a correlation between the appearance of somatic hypermutations in the Ig genes and the presence of mutations in the 5'-noncoding region of the BCL-6 gene.1,3-5 Consequently, this correlation can also be observed in B-cell non-Hodgkin lymphoma (NHL), such as FL and DLBCL, which carry high loads of mutations in their Ig genes.3,5 The precise role of BCL-6 in the pathogenesis of the NHL is, however, not yet clear. CHD represents a lymphoma entity that is derived from B cells with highly mutated Ig genes in most instances (approximately 98%) and from T cells in a few cases (approximately 2%).12 To determine whether B-cell-derived cHD cases, as well as T-cell-derived cHD cases, carry mutations in their 5'-noncoding region of the BCL-6 gene, we isolated 202 single HRS cells from 6 patients with cHD. Four of these patients harbored HRS cells of B-cell genotype, whereas 2 further patients harbored HRS cells of T-cell genotype.12 For comparison, 6 HD cell lines (4 with B-cell genotype and 2 with T-cell genotype) were included in this study, and 201 single reactive cells were analyzed. The results obtained were equivocal in that all patients with B-cell-derived HD and HD cell lines of B-cell type were found to carry somatic BCL-6 mutations. In contrast, patients with T-cell-derived HD and cell lines were devoid of base substitutions in the BCL-6 gene as well as T cells isolated from the GC. This indicates that reactive GC T cells are not affected by the mutational machinery, whereas this has already been demonstrated for reactive GC B cells in previous investigations.1,2 The finding of BCL-6 mutations in patients with B-cell-derived HD raises the question of the role these alterations play in the pathogenesis of HD. For this purpose we analyzed the position of the BCL-6 mutations and compared these findings with previously published data described for B-cell NHL5 as well as with the BCL-6 sequences obtained from nonmalignant cells of our own cHD cases. In 3 of 4 B-cell-type HD cases, the detected BCL-6 mutations represent single base substitutions not previously described or which are located in known mutational hotspots (RGWY motif).5 These alterations can be considered as irrelevant somatic mutations not affecting the expression of the BCL-6 gene. In the remaining case, however, a deletion of thymidine (T) at position 520 (520delT), which is described as the most common recurrent mutation in B-cell NHL, was found.5 This deletion might cause an up-regulation of BCL-6 gene expression, ie, by the generation of a new transcription factor binding site (eg, MZF1). This assumption is in harmony with the results of the protein expression analysis in this case because a strong expression of BCL-6 was found in virtually all tumor cells. In contrast, in all other B-cell-derived cHD cases, the HRS cells were negative for BCL-6 with the exception of a few scattered tumor cells. The absence of relevant BCL-6 mutations, as well as the
absence of BCL-6 protein expression, in all but one case of the B-cell genotype challenge the role of BCL-6 in the pathogenesis of
cHD. Based on previous data it can be assumed that HRS cells represent late GC B cells that were not selected for antigen affinity and carry
nonfunctional Ig rearrangements in approximately 30% of cases.17,18 Furthermore it was shown that the absence of
Ig expression is not due to crippled Ig
mutations, but rather to a defective transcription
machinery.17 The absence of BCL-6 expression fits well in
this scenario because late GC B cells and post-GC B cells are largely
BCL-6 The complete absence of BCL-6 mutations in T-cell-derived cHD cases clearly indicates that alterations in this gene are not involved in the pathogenesis of this type of HD. The finding that one of the 2 T-cell-derived HD cases showed, despite the absence of BCL-6 mutations, an expression of BCL-6 could reflect a derivation from BCL-6+ (GC) T cells. Because reactive GC T cells do not carry BCL-6 mutations, they are not affected by the mutational machinery responsible for Ig mutations. This is in contrast to the findings in cHD of B-cell type, where the transformational event seems to be closely related to the activity of the GC mutator.20,21 We conclude from these findings that the molecular events that are responsible for the pathogenesis of B-cell-derived cHD are different from those giving rise to T-cell-derived cHD. In conclusion, our data show that B-cell-derived cHD cases carry somatic mutations in the 5'-noncoding region of the BCL-6 gene, whereas T-cell-derived cHD cases, as well as GC T cells, were unmutated. This supports a 2-entity concept for B- and T-cell-derived cHD. Because only one case carried a lymphoma-specific recurrent mutation and BCL-6 was absent from the HRS cells in most cases, BCL-6 does not appear to be relevant for the pathogenesis of both B-cell- and T-cell-type cHD.
We are indebted to D. Jahnke, H. Lammert, and H. Protz for their excellent technical assistance and L. Udvarhelyi for his editorial help.
Submitted July 31, 2000; accepted November 13, 2000.
Sponsored by a grant (70-2202-Mü3) from Deutsche Krebshilfe, Bonn, Germany, and by a grant (9917155) from Berliner Krebsgesellschaft, Berlin, Germany.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Harald Stein, Institute of Pathology, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200 Berlin, Germany; e-mail: stein{at}medizin.fu-berlin.de.
1.
Pasqualucci L, Migliazza A, Fracchiolla N, et al.
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.
Proc Natl Acad Sci U S A.
1998;95:11816-11821
2.
Shen HM, Peters A, Baron B, Zhu X, Storb U.
Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.
Science.
1998;280:1750-1752
3.
Migliazza A, Martinotti S, Chen W, et al.
Frequent somatic hypermutation of the 5' noncoding region of the BCL-6 gene in B-cell lymphoma.
Proc Natl Acad Sci U S A.
1995;92:12520-12524
4.
Szereday Z, Csernus B, Nagy M, Laszlo T, Warnke RA, Matolcsy A.
Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma.
Am J Pathol.
2000;156:1017-1024
5.
Lossos IS, Levy R.
Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity.
Blood.
2000;95:1400-1405
6.
Lo CF, Ye BH, Lista F, et al.
Rearrangements of the BCL-6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
1994;83:1757-1759
7.
Capello D, Vitolo U, Pasqualucci L, et al.
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.
Blood.
2000;95:651-659
8.
Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H.
Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells [see comments].
N Engl J Med.
1995;333:901-906
9.
Kuppers R, Rajewsky K, Zhao M, et al.
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development.
Proc Natl Acad Sci U S A.
1994;91:10962-10966
10.
Kanzler H, Hansmann ML, Kapp U, et al.
Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.
Blood.
1996;87:3429-3436
11.
Muschen M, Rajewsky K, Brauninger A, et al.
Rare occurrence of classical Hodgkin's disease as a T cell lymphoma.
J Exp Med.
2000;191:387-394
12.
Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H.
Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease.
Blood.
2000;95:3020-3024
13.
Carbone A, Gloghini A, Gaidano G, et al.
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease.
Blood.
1998;92:2220-2228 14. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229[Abstract]. 15. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994;173:371-379[CrossRef][Medline] [Order article via Infotrieve].
16.
Marafioti T, Hummel M, Anagnostopoulos I, et al.
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells [see comments].
N Engl J Med.
1997;337:453-458
17.
Marafioti T, Hummel M, Foss HD, et al.
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
2000;95:1443-1450
18.
Kanzler H, Kuppers R, Hansmann ML, Rajewsky K.
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.
J Exp Med.
1996;184:1495-1505
19.
Falini B, Bigerna B, Pasqualucci L, et al.
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
Blood.
1996;87:465-471
20.
Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Huhn D, Stein H.
Classical Hodgkin disease and follicular lymphoma originating from the same germinal center B cell.
J Clin Oncol.
1999;17:3804-3809
21.
Brauninger A, Hansmann ML, Strickler JG, et al.
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma [see comments].
N Engl J Med.
1999;340:1239-1247
22.
Wolf J, Kapp U, Bohlen H, et al.
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.
Blood.
1996;87:3418-3428
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells Am. J. Pathol., February 1, 2008; 172(2): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Margalit, H. Amram, N. Amariglio, A. J. Simon, S. Shaklai, G. Granot, N. Minsky, A. Shimoni, A. Harmelin, D. Givol, et al. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1599 - 1607. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-F1 positivity. The sequence analysis of
the 5 resulting BCL-6 PCR products disclosed that none of
these cells displayed somatic mutations introduced in the GC environment.